Use of ultrafiltration/diafiltration for the processing of antisense oligonucleotides

被引:4
|
作者
Gronke, Robert S. [1 ]
Ruanjaikaen, Krisada [2 ]
Delavari, Armin [1 ]
Immel-Brown, Jonas P. [1 ]
Penrod, Joseph C. [3 ]
Lam, Yik [3 ]
Antia, Firoz D. [1 ]
机构
[1] Biogen Inc, Tech Dev, Cambridge, MA 02142 USA
[2] Intellia Therapeut Inc, Tech Operat, Cambridge, MA USA
[3] Biogen Inc, Tech Dev, Durham, NC USA
关键词
membrane polarization; oligonucleotide; ultrafiltration and diafiltration; MEMBRANES; PROTEIN;
D O I
10.1002/btpr.3350
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Ultrafiltration/diafiltration (UF/DF) has been the hallmark for concentrating and buffer exchange of protein and peptide-based therapeutics for years. Here we examine the capabilities and limitations of UF/DF membranes to process oligonucleotides using antisense oligonucleotides (ASOs) as a model. Using a 3 kDa UF/DF membrane, oligonucleotides as small as 6 kDa are shown to have low sieving coefficients (<0.008) and thus can be concentrated to high concentrations (= 200 mg/mL) with high yield (= 95%) and low viscosity (<15 centipoise), provided the oligonucleotide is designed not to undergo self-hybridization. In general, the oligonucleotide should be at least twice the reported membrane molecular weight cutoff for robust retention. Regarding diafiltration, results show that a small amount of salt is necessary to maintain adequate flux at concentrations exceeding about 40 mg/mL. Removal of salts along with residual solvents and small molecule process-related impurities can be robust provided they are not positively charged as the interaction with the oligonucleotide can prevent passage through the membrane, even for common divalent cations such as calcium or magnesium. Overall, UF/DF is a valuable tool to utilize in oligonucleotide processing, especially as a final drug substance formulation step that enables a liquid active pharmaceutical ingredient.
引用
收藏
页数:12
相关论文
共 50 条
  • [21] Use of antisense oligonucleotides: Advantages, controls, and cardiovascular tissue
    Golden, T
    Dean, NM
    Honkanen, RE
    MICROCIRCULATION, 2002, 9 (01) : 51 - 64
  • [22] Animal models of antisense oligonucleotides: Lessons for use in humans
    Plenat, F
    MOLECULAR MEDICINE TODAY, 1996, 2 (06): : 250 - 257
  • [23] Water usage in variable volume diafiltration: comparison with ultrafiltration and constant volume diafiltration
    Foley, Greg
    DESALINATION, 2006, 196 (1-3) : 160 - 163
  • [24] Ultrafiltration with variable volume diafiltration: a novel approach to water saving in diafiltration processes
    Foley, Greg
    DESALINATION, 2006, 199 (1-3) : 220 - 221
  • [25] Predicting Diafiltration Solution Compositions for Final Ultrafiltration/Diafiltration Steps of Monoclonal Antibodies
    Teeters, Mark
    Bezila, Daniel
    Benner, Terry
    Alfonso, Pedro
    Alred, Patricia
    BIOTECHNOLOGY AND BIOENGINEERING, 2011, 108 (06) : 1338 - 1346
  • [26] PREPARATION OF RAPESEED PROTEINS BY EXTRACTION, ULTRAFILTRATION AND DIAFILTRATION
    KROLL, J
    KUJAWA, M
    SCHNAAK, W
    FETT WISSENSCHAFT TECHNOLOGIE-FAT SCIENCE TECHNOLOGY, 1991, 93 (02): : 61 - 64
  • [27] Ultrafiltration diafiltration: Process characterization and process validation
    Begum, Zahira
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2016, 251
  • [28] BLOOD PURIFICATION BY ULTRAFILTRATION AND FLUID REPLACEMENT (DIAFILTRATION)
    HENDERSO.LW
    BESARAB, A
    MICHAELS, A
    BLUEMLE, LW
    TRANSACTIONS AMERICAN SOCIETY FOR ARTIFICIAL INTERNAL ORGANS, 1967, 13 (APR): : 216 - &
  • [29] Determination of time optimal diafiltration for an ultrafiltration process
    Foust, Henry
    Bakeer, Reda
    Drakunov, Sergey
    Proceedings of the ASME Fluids Engineering Division Summer Conference - 2005, Vol 1, Pts A and B, 2005, : 959 - 964
  • [30] High throughput screening of ultrafiltration and diafiltration processing of monoclonal antibodies via the ambr® crossflow system
    Fernandez-Cerezo, Lara
    Wismer, Michael K.
    Han, InKwan
    Pollard, Jennifer M.
    BIOTECHNOLOGY PROGRESS, 2020, 36 (02)